Promising Phase 1 Results for Hemophilia A Gene Therapy
Expression Therapeutics announced promising Phase 1 clinical trial results for its novel gene therapy, ET3, treating hemophilia A. The trial, detailed in the New England Journal of Medicine, showed significant increases in Factor VIII levels and a reduction in bleeding events in participants with severe hemophilia A. The therapy uses a lentiviral vector targeting hematopoietic stem […]
CRISPR Therapeutics’ FDA Approval for CASGEVY™
CRISPR Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving CASGEVY™ (exagamglogene autotemcel [exa-cel]), a groundbreaking CRISPR/Cas9 gene-edited cell therapy. This approval makes CASGEVY available for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older. Approximately 1,000 patients in the U.S. are now eligible for […]
Stem Cell Transplant as a Curative Treatment for Sickle Cell Disease
Hosted by Expecting Health in collaboration with Be The Match, this webinar delved into the current practices and considerations surrounding bone marrow transplant as a potential curative treatment for Sickle Cell disease. The session aimed to shed light on the intricacies of the transplant process and to amplify awareness within the newborn screening community. Speakers: […]
Caring Cross Unveils Affordable Genetic Therapy Strategies
New press release announces the role of Caring Cross, a non-profit organization, in a newly published white paper from the Innovative Genomics Institute, titled “Making Genetic Therapies Affordable and Accessible.” The white paper is the result of yearlong research and focuses on strategies to increase the affordability and accessibility of genetic therapies, including CAR-T technology […]
RoslinCT and Lykan Bioscience: The Dynamic Duo Redefining the Future of Cell and Gene Therapy
RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand. This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell […]
reNEW | Next generation stem cell research
reNEW is a unique global collaboration focusing on stem cell research involving three leading research institutions: the University of Copenhagen in Denmark, the Leiden University Medical Center in the Netherlands, and the Murdoch Children’s Research Institute in Australia. reNEW’s vision is to create a new generation of effective, safe, and socially sustainable stem cell-based therapies […]
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts
San Diego, California and London, UK, October 17, 2022 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has established a scientific advisory board (SAB) comprising ten experts across a broad range of areas of scientific importance in genomic medicine and cell therapy. The newly formed SAB will provide input into […]
StemExpress Opens New Collection Center in Biotech Hub of Boston, MA
CAMBRIDGE, Mass., Sept. 15, 2022 /PRNewswire/ — StemExpress is excited to announce the opening of their newest StemExpress cell collection center in Boston, Massachusetts. StemExpress is relocating from Arlington, MA to the prestigious research hub of Cambridge, MA. The move promises more partnerships and better logistics for client needs, opening doors for more scalable cell […]
Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio will be featured at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place from August 30 to September 2, 2022, in Freiburg, […]
Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board
SAN DIEGO, July 26, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of geneticist George M. Church, Ph.D., who will serve as Chair of Poseida’s newly formed Gene Therapy Scientific Advisory […]